Testosterone and Prostate Cancer: Separating Myth from Evidence

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

Modern evidence challenges the old myth that TRT causes prostate cancer. The saturation model suggests that once androgen receptors are full, more testosterone doesn't fuel cancer growth.

Testosterone and Prostate Cancer: Separating Myth from Evidence

The relationship between testosterone and prostate cancer has been a subject of intense debate and concern for decades. For many years, a prevailing dogma, often referred to as the "androgen hypothesis," suggested that testosterone fueled prostate cancer growth, leading to the widespread belief that Testosterone Replacement Therapy (TRT) was contraindicated in men with prostate cancer or even those at high risk. This fear largely stemmed from a 1941 study by Huggins and Hodges, which demonstrated that orchiectomy (testicular removal) or estrogen administration could cause prostate cancer regression, while testosterone administration could exacerbate it in advanced cases. However, modern research has significantly challenged and refined this understanding.

The traditional view held that prostate cancer growth was directly proportional to testosterone levels. This linear model suggested that higher testosterone meant faster cancer growth. However, contemporary research, particularly the "saturation model" proposed by Morgentaler and Traish, offers a more nuanced perspective. This model posits that prostate cancer cells have a finite number of androgen receptors, and once these receptors are saturated at relatively low testosterone concentrations (e.g., around 200-250 ng/dL), further increases in testosterone levels do not lead to additional stimulation of cancer cell growth. In essence, the receptors are already maximally stimulated, and adding more fuel (testosterone) does not make the fire burn hotter.

Modern Evidence and Clinical Practice

Numerous studies in recent years have provided compelling evidence that contradicts the old androgen hypothesis:

• TRT in Men with Treated Prostate Cancer: A growing body of literature, including meta-analyses, has shown that TRT in men with a history of treated prostate cancer (e.g., after radical prostatectomy or radiation therapy) does not increase the risk of recurrence. These studies typically involve careful patient selection, ensuring undetectable PSA levels and no evidence of active disease.
• TRT and Prostate Cancer Incidence: Large observational studies and analyses have failed to demonstrate a causal link between TRT and an increased risk of developing prostate cancer in men without a prior diagnosis. In fact, some research suggests that men with higher endogenous testosterone levels may have a lower risk of aggressive prostate cancer.
• Active Surveillance and TRT: For men on active surveillance for low-risk prostate cancer, TRT has been cautiously explored. While still a specialized area, initial data suggests that TRT may be safe in carefully selected men under strict monitoring, without accelerating disease progression.
• The "Testosterone Window": It has been observed that both very low and very high testosterone levels might be associated with adverse prostate outcomes. Maintaining physiological testosterone levels within the normal range (e.g., 300-1000 ng/dL) appears to be the safest approach.

Monitoring and Patient Selection

Despite the evolving understanding, careful patient selection and rigorous monitoring remain paramount when considering TRT, especially in men with prostate concerns. Before initiating TRT, a thorough prostate evaluation is essential, including a digital rectal exam (DRE) and Prostate-Specific Antigen (PSA) testing. Men with elevated PSA or abnormal DRE findings should undergo further investigation, potentially including prostate biopsy, before TRT is considered.

During TRT, regular monitoring of PSA levels and DREs is standard practice. Any significant or sustained increase in PSA should prompt further evaluation for potential prostate pathology. It is crucial for men to have an open and detailed discussion with their urologist and endocrinologist about their individual risk factors, prostate health history, and the latest evidence regarding TRT and prostate cancer. The decision to initiate or continue TRT in men with prostate cancer or at high risk should always be a shared one, based on a comprehensive assessment of benefits and risks.